Anika Therapeutics (ANIK) Shares Fall on FDA Timing Uncertainty
Tweet
Share
E-mailGet Alerts ANIK Hot Sheet
Join SI Premium – FREE
Anika Therapeutics, Inc. (Nasdaq: ANIK) shares are showing selling after-hours today following an announcement by the company that they still have not received timing for an FDA Advisory Panel meeting for MONOVISC. Additionally, the company said that the FDA did not approve their Bedford Facility, and will not until the equipment is permanently installed in Bedford. Finally, Anika said that they don't have timing set for three 510(k) premarket notifications filed for Anika Therapeutics S.r.l. products in October 2010. They were anticipating clearance for one at the end of 2010, and two before the end of Q111.
Shares are down 10.7% post-market.
Click here for full color from the release.
Shares are down 10.7% post-market.
Click here for full color from the release.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Anika to Issue Second Quarter 2026 Financial Results on Wednesday, July 29, 2026
- Lilly’s Retevmo approved by FDA for RET Tumors
- Susquehanna Starts IBM (IBM) at Neutral
Create E-mail Alert Related Categories
FDA, Insiders' Blog, Momentum MoversSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
